- Home
- FLC vs DTIL Comparison
FLC vs DTIL Comparison
Compare FLC & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FLC | DTIL |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.0M | 194.3M |
| IPO Year | 2003 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FLC | DTIL |
|---|---|---|
| Price | $17.08 | $7.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | 23.3K | ★ 232.9K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.92 | $3.53 |
| 52 Week High | $18.09 | $8.82 |
Technical Indicators
Market Signals| Indicator | FLC | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 50.75 | 55.65 |
| Support Level | $16.87 | $4.56 |
| Resistance Level | $17.24 | $7.84 |
| Average True Range (ATR) | 0.13 | 0.53 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 59.70 | 59.50 |
Price Performance
Historical ComparisonAbout FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).